Cangene Report issue

Contributed to NME For profit Phase 1 Phase 3 Phase 4
Founded: Winnipeg Canada (1984)
Status: Acquired by Emergent BioSolutions (2013)

Organization Overview

First Clinical Trial
2006
NCT00338442
First Marketed Drug
2005
vaccinia immunoglobulin
First NDA Approval
2005
vaccinia immunoglobulin
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cangene Corporation | Cangene Corporation a subsidiary of Emergent BioSolutions Inc | Cangene Corporation (doing business as Emergent BioSolutions) | Cangene Plasma Resources, Mid-Florida

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anthrax (Phase 1)

Botulism (Phase 1)

Hemophilia A (Phase 3)

Hemophilia B (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Paralysis (Phase 1)

Smallpox (Phase 4)

Vaccinia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 9